In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...
CTS merges with the three Red Cross testing laboratories located in Charlotte, Portland and St. Loui...